People In Brief
This article was originally published in The Tan Sheet
Executive Summary
Wyeth promotes executives: Cavan Redmond will begin his tenure as the Madison, N.J.-based drug firm's Consumer Healthcare group president in January and Joseph Mahady will head the Pharmaceuticals division, among other management changes, Wyeth announces Nov. 30. Redmond will be responsible for the division's global operations, among other duties, the firm states. His previous positions include executive VP and general manager of the BioPharma business unit of Wyeth Pharmaceuticals as well as "positions of increasing responsibility" in the R&D and commercial divisions, Wyeth says. Mahady, elected both as president of Wyeth Pharmaceuticals and senior VP of the firm, began his career with Wyeth in 1979 as a pharmacist in regulatory affairs and most recently worked as the pharmaceutical division's global business president. The Madison, N.J.-based firm announced the election of Bernard Poussot as CEO and president in September (1"The Tan Sheet" Oct. 1, 2007, In Brief). Currently president, chief operating officer and vice chairman, Poussot, like the other recently promoted executives, will begin serving in his new capacity Jan. 1...
You may also be interested in...
Wyeth names new CEO
Wyeth announced Sept. 27 that Bernard Poussot will assume the position of CEO and president as of Jan. 1, 2008. Poussot will replace Robert Essner, who was elected CEO in May 2001 and became chairman in January 2003. Poussot began his career at Wyeth in 1986, and held positions including executive vice president until January 2007, when he was promoted to president, chief operating officer and vice chairman of Wyeth (1"The Tan Sheet" Jan. 29, 2007, In Brief). Essner will remain in his positions at Wyeth until Poussot's Jan. 1 start-date...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands